Skip to main content

Table 2 Toxicity during the course of chemoradiation

From: A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

  Grade 1 Grade 2 Grade 3
n % n % n %
Diarrhea 15 35.71% 12 28.57% 5 11.90%
Hematologic 8 19.05% 8 19.05% 1 2.38%
Fatigue 8 19.05% 5 11.90% 3 7.14%
Radiation dermatitis 5 11.90% 18 42.86% 9 21.43%
Neurosensory 1 2.38% 1 2.38% 1 2.38%
Hand-foot syndrome 2 4.76% 0 0.00% 0 0.00%